viewMotif Bio PLC

Motif Bio to present three iclaprim posters at industry conference in San Francisco next month

The three posters will contain data on Motif Bio’s lead product, a next-generation antibiotic

US regulators want more liver toxicity data before they approve iclamprim

UK biopharma Motif Bio PLC (LON:MTFB) is to present three posters on its iclaprim next-generation antibiotic at an upcoming industry conference in San Francisco.

The American Society for Microbiology (ASM) Microbe 2019 meeting runs from 20 to 24 June. Motif bosses will be presenting their posters on 21 and 22 June.

READ: Motif bosses meet with FDA

AIM- and Nasdaq-listed Motif met with the US Food and Drug Administration (FDA) earlier this month as it looks to secure regulatory approval for iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI).

The company sought talks after the FDA declined to give the antibiotic the green light, citing in a document the need for additional data on liver toxicity.

As one of Motif’s advisers pointed out, this wasn’t a straight ‘no’. The firm has always said it was keen to discuss potential deficiencies with the information provided.

The latest meeting, which took place on 3 May, offered that chance, with feedback expected within 30 days.

Quick facts: Motif Bio PLC

Price: 0.53 GBX

Market: AIM
Market Cap: £2.57 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...



Motif Bio announces US FDA approval deadline for its antibiotic drug

Motif Bio (LON:MTFB, NASDAQ: MTFB) CEO Graham Lumsden tells Proactive Investors the US FDA has begun the process of assessing whether the company’s next-generation antibiotic should be allowed to go on sale in the US. Motif's drug iclaprim has been granted a priority review by the...

on 08/15/2018


Holding(s) in Company

6 days, 12 hours ago

Holding(s) in Company

1 week, 6 days ago

Total Voting Rights

1 week, 6 days ago

Holding(s) in Company

3 weeks, 1 day ago

Directorate Changes

3 weeks, 3 days ago

2 min read